Small Molecule Modalities

Capabilities include peptide synthesis (SPPS, LPPS, and hybrid approaches), ADC payload and linker development with high-potency handling, and biocatalytic process development using enzyme-driven transformations.

Each modality introduces specific requirements for route selection, impurity control, and scalability. Process development is structured to ensure reproducibility, yield optimization, and alignment with downstream manufacturing requirements.

Peptide processes are developed using solid-phase and liquid-phase synthesis approaches, followed by purification strategies designed to meet sequence complexity, purity specifications, and scale requirements.

A peptide CDMO supports scale-up by developing robust synthesis and purification processes that maintain yield, purity, and reproducibility as production volumes increase. 

Development involves multi-step synthesis under controlled conditions, with a focus on containment, impurity management, and reproducibility to support safe handling of high-potency compounds.

Biocatalysis uses enzyme-mediated reactions to enable selective transformations, reduce process steps, and support more controlled reaction conditions compared to traditional synthetic routes.

Processes are evaluated for robustness, scalability, and consistency, with defined parameters to support transfer from development to clinical and commercial manufacturing.

Yes, development strategies are structured to support progression from early-stage process development through clinical manufacturing and commercial scale production.